(AMBQ) Ambiq Micro - Overview
Sector: Technology | Industry: Semiconductors | Exchange: NYSE (USA) | Market Cap: 1.746m USD | Total Return: 109.1% in 12m
Avg Turnover: 60.7M
Rev. Trend: 66.5%
Warnings
Share dilution 49.9% YoY
High Debt while negative Cash Flow
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Supp Ema8, Supp Ema20, Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w, Confidence
Ambiq Micro, Inc. (AMBQ) specializes in ultra-low-power semiconductor solutions utilizing its proprietary Sub-threshold Power-optimized Technology (SPOT) platform. The company designs systems-on-chips (SoC) and software development kits specifically for battery-operated devices that require high-performance AI computation with minimal energy consumption. Its primary product lines, Apollo and Atomiq, target diverse end markets including wearable electronics, digital health monitors, and industrial automation.
The company operates within the fabless semiconductor business model, focusing on research and design while outsourcing physical manufacturing to specialized foundries. This sector is currently driven by the rapid expansion of the Internet of Things (IoT) and the increasing demand for edge computing, where data is processed locally on the device rather than in the cloud to reduce latency and power draw.
For a deeper dive into the companys financial health and valuation metrics, consider reviewing the detailed data available on ValueRay.
Headquartered in Austin, Texas, Ambiq distributes its hardware and AI enablement software through a combination of a direct sales force and global distribution networks. The firm supports its hardware with a comprehensive suite of software modules for Bluetooth, security, and graphics management, positioning itself as a full-stack provider for low-power intelligent devices.
- Adoption of SPOT technology in wearable devices drives core revenue growth
- Expansion of on-device AI capabilities increases average selling price per unit
- Market penetration in industrial IoT and digital health diversifies customer base
- Global semiconductor supply chain constraints impact production costs and lead times
- Competition from established chipmakers threatens market share in power-efficient computing
| Net Income: -38.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 6.12 > 1.0 |
| NWC/Revenue: 270.0% < 20% (prev 89.34%; Δ 180.7% < -1%) |
| CFO/TA -0.12 > 3% & CFO -32.3m > Net Income -38.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.4m) vs 12m ago 49.86% < -2% |
| Gross Margin: 42.28% > 18% (prev 0.30%; Δ 4.20k% > 0.5%) |
| Asset Turnover: 45.62% > 50% (prev 77.13%; Δ -31.51% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.85 (Total Current Assets 241.7m - Total Current Liabilities 20.6m) / Total Assets 259.5m |
| B: -1.41 (Retained Earnings -366.9m / Total Assets 259.5m) |
| C: -0.24 (EBIT TTM -42.5m / Avg Total Assets 179.4m) |
| D: -15.07 (Book Value of Equity -367.3m / Total Liabilities 24.4m) |
| Altman-Z'' = -16.44 = D |
| DSRI: 2.53 (Receivables 11.0m/4.06m, Revenue 81.8m/76.6m) |
| GMI: 0.72 (GM 42.28% / 30.42%) |
| AQI: 0.41 (AQ_t 0.05 / AQ_t-1 0.11) |
| SGI: 1.07 (Revenue 81.8m / 76.6m) |
| TATA: -0.02 (NI -38.3m - CFO -32.3m) / TA 259.5m) |
| Beneish M = -2.34 (Cap -4..+1) = BBB |
As of May 28, 2026, the stock is trading at USD 80.57 with a total of 861,230 shares traded.
Over the past week, the price has changed by +13.26%,
over one month by +131.39%,
over three months by +162.44% and
over the past year by +109.11%.
Ambiq Micro has no consensus analysts rating.
P/S = 21.3308
P/B = 7.4237
Revenue TTM = 81.8m USD
EBIT TTM = -42.5m USD
EBITDA TTM = -35.5m USD
Long Term Debt = 1.16m USD (estimated: total debt 2.14m - short term 982k)
Short Term Debt = 982k USD (from shortTermDebt, last quarter)
Debt = 2.14m USD (from shortLongTermDebtTotal, last quarter) (leases 2.14m already included)
Net Debt = -202.4m USD (calculated: Debt 2.14m - CCE 204.5m)
Enterprise Value = 1.54b USD (1.75b + Debt 2.14m - CCE 204.5m)
Interest Coverage Ratio = unknown (Ebit TTM -42.5m / Interest Expense TTM 0.0)
EV/FCF = -43.15x (Enterprise Value 1.54b / FCF TTM -35.8m)
FCF Yield = -2.32% (FCF TTM -35.8m / Enterprise Value 1.54b)
FCF Margin = -43.70% (FCF TTM -35.8m / Revenue TTM 81.8m)
Net Margin = -46.86% (Net Income TTM -38.3m / Revenue TTM 81.8m)
Gross Margin = 42.28% ((Revenue TTM 81.8m - Cost of Revenue TTM 47.2m) / Revenue TTM)
Gross Margin QoQ = 43.46% (prev 42.71%)
Tobins Q-Ratio = 5.95 (Enterprise Value 1.54b / Total Assets 259.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.14m)
Taxrate = 21.0% (US default 21%)
NOPAT = -33.6m (EBIT -42.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.70 (Total Current Assets 241.7m / Total Current Liabilities 20.6m)
Debt / Equity = 0.01 (Debt 2.14m / totalStockholderEquity, last quarter 235.2m)
Debt / EBITDA = 5.71 (negative EBITDA) (Net Debt -202.4m / EBITDA -35.5m)
Debt / FCF = 5.66 (negative FCF - burning cash) (Net Debt -202.4m / FCF TTM -35.8m)
Total Stockholder Equity = 159.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.37% (Net Income -38.3m / Total Assets 259.5m)
RoE = -7.28% (Net Income TTM -38.3m / Total Stockholder Equity 526.4m)
RoCE = -8.05% (EBIT -42.5m / Capital Employed (Equity 526.4m + L.T.Debt 1.16m))
RoIC = -94.99% (negative operating profit) (NOPAT -33.6m / Invested Capital 35.3m)
WACC = 19.64% (E(1.75b)/V(1.75b) * Re(19.66%) + D(2.14m)/V(1.75b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 19.66% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 43.52 | Cagr: 22.42%
[DCF] Fair Price = unknown (Cash Flow -35.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 66.49 | Revenue CAGR: 5.19% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.26 | Chg30d=+38.34% | Revisions=+43% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.28 | Chg30d=+40.37% | Revisions=+43% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.11 | Chg30d=+34.28% | Revisions=+43% | GrowthEPS=+57.6% | GrowthRev=+68.0%
EPS next Year (2027-12-31): EPS=-0.75 | Chg30d=+34.72% | Revisions=+43% | GrowthEPS=+32.2% | GrowthRev=+25.3%
[Analyst] Revisions Ratio: +43%